World's Best Scientists 2026 revealed!
François A. Lemonnier

François A. Lemonnier

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Immunology 69 2507 2304 104 92 209 17058

François A. Lemonnier publications per year

The chart shows the history of publications by François A. Lemonnier between 1963 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. François A. Lemonnier published across 63 years, from 1963 to 2025, averaging 3.7 papers a year. Output peaked at 18 publications in 2004. 13 of the 235 publications appeared in the last two years.

No. of publications
5 10 15
Bar chart. Horizontal axis: year, 1963 to 2025. Vertical axis: number of publications, 0 to 18. Peak 18 publications in 2004. 1963: 1 publication 1964: 1 publication 1965: 0 publications 1966: 0 publications 1967: 0 publications 1968: 0 publications 1969: 0 publications 1970: 0 publications 1971: 1 publication 1972: 0 publications 1973: 0 publications 1974: 1 publication 1975: 2 publications 1976: 1 publication 1977: 1 publication 1978: 4 publications 1979: 0 publications 1980: 0 publications 1981: 2 publications 1982: 2 publications 1983: 7 publications 1984: 5 publications 1985: 3 publications 1986: 1 publication 1987: 3 publications 1988: 5 publications 1989: 4 publications 1990: 3 publications 1991: 2 publications 1992: 1 publication 1993: 1 publication 1994: 0 publications 1995: 1 publication 1996: 2 publications 1997: 5 publications 1998: 4 publications 1999: 17 publications 2000: 11 publications 2001: 8 publications 2002: 11 publications 2003: 11 publications 2004: 18 publications 2005: 14 publications 2006: 12 publications 2007: 11 publications 2008: 3 publications 2009: 6 publications 2010: 1 publication 2011: 3 publications 2012: 6 publications 2013: 5 publications 2014: 2 publications 2015: 3 publications 2016: 3 publications 2017: 2 publications 2018: 2 publications 2019: 2 publications 2020: 0 publications 2021: 1 publication 2022: 0 publications 2023: 7 publications 2024: 4 publications 2025: 9 publications
1963 2025

235 publications in total across all disciplines

View publications per year as a table
François A. Lemonnier: publications per year, 1963 to 2025
Year Publications
1963 1
1964 1
1965 0
1966 0
1967 0
1968 0
1969 0
1970 0
1971 1
1972 0
1973 0
1974 1
1975 2
1976 1
1977 1
1978 4
1979 0
1980 0
1981 2
1982 2
1983 7
1984 5
1985 3
1986 1
1987 3
1988 5
1989 4
1990 3
1991 2
1992 1
1993 1
1994 0
1995 1
1996 2
1997 5
1998 4
1999 17
2000 11
2001 8
2002 11
2003 11
2004 18
2005 14
2006 12
2007 11
2008 3
2009 6
2010 1
2011 3
2012 6
2013 5
2014 2
2015 3
2016 3
2017 2
2018 2
2019 2
2020 0
2021 1
2022 0
2023 7
2024 4
2025 9
Total 235
Download as CSV

François A. Lemonnier publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where François A. Lemonnier sits on this spectrum.

No. of scientists
50 100 150
Bar chart with 76 bars. Horizontal axis: publications, 62–71 to 807+. Vertical axis: number of scientists, 0 to 189. Most scientists, 189, have 152–161 publications. The last bar groups every scientist with 807 publications or more. The highlighted bar, 202–211 publications, is where this scientist sits. 62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientist 807+ publications: 100 scientists
62–71 publications 807+

This scientist: 209 publications — 38th percentile

38% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

View publications distribution as a table
Number of Immunology scientists by publication count, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
Publications Scientists This scientist
62–71 9
72–81 23
82–91 40
92–101 72
102–111 86
112–121 108
122–131 150
132–141 160
142–151 159
152–161 189
162–171 166
172–181 181
182–191 188
192–201 187
202–211 178 209
212–221 158
222–231 168
232–241 159
242–251 160
252–261 148
262–271 116
272–281 125
282–291 115
292–301 111
302–311 95
312–321 97
322–331 97
332–341 99
342–351 96
352–361 69
362–371 76
372–381 71
382–391 71
392–401 62
402–411 54
412–421 41
422–431 63
432–441 53
442–451 31
452–461 42
462–471 40
472–481 29
482–491 34
492–501 30
502–511 23
512–521 41
522–531 29
532–541 28
542–551 16
552–561 18
562–571 18
572–581 17
582–591 17
592–601 17
602–611 19
612–621 13
622–631 12
632–641 11
642–651 16
652–661 9
662–671 5
672–681 13
682–691 12
692–701 6
702–711 6
712–721 9
722–731 9
732–741 6
742–751 11
752–761 10
762–771 7
772–781 12
782–791 7
792–801 5
802–806 1
807+ 100
Download as CSV

François A. Lemonnier D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where François A. Lemonnier sits on this spectrum.

No. of scientists
50 100 150 200
Bar chart with 60 bars. Horizontal axis: D-Index, 40–41 to 157+. Vertical axis: number of scientists, 0 to 201. Most scientists, 201, have 58–59 D-Index. The last bar groups every scientist with 157 D-Index or more. The highlighted bar, 68–69 D-Index, is where this scientist sits. 40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40–41 D-Index 157+

This scientist: 69 D-Index — 50th percentile

50% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

View D-Index distribution as a table
Number of Immunology scientists by D-index, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
D-Index Scientists This scientist
40–41 28
42–43 91
44–45 157
46–47 192
48–49 175
50–51 188
52–53 177
54–55 155
56–57 194
58–59 201
60–61 197
62–63 201
64–65 173
66–67 167
68–69 172 69
70–71 199
72–73 184
74–75 133
76–77 163
78–79 127
80–81 121
82–83 125
84–85 121
86–87 102
88–89 96
90–91 75
92–93 72
94–95 74
96–97 66
98–99 68
100–101 49
102–103 60
104–105 54
106–107 36
108–109 23
110–111 52
112–113 41
114–115 34
116–117 25
118–119 28
120–121 11
122–123 20
124–125 27
126–127 19
128–129 20
130–131 16
132–133 17
134–135 14
136–137 15
138–139 9
140–141 11
142–143 9
144–145 9
146–147 7
148–149 7
150–151 7
152–153 5
154–155 8
156 6
157+ 96
Download as CSV

Overview

François A. Lemonnier is affiliated with Université Paris Cité in France and conducts research primarily in the field of Medicine. Their work covers several subfields including Pathology and Forensic Medicine, Oncology, Molecular Biology, Immunology, and Genetics.

Their research topics cover a variety of specialized areas, notably:

  • Lymphoma Diagnosis and Treatment
  • CAR-T cell therapy research
  • Viral-associated cancers and disorders
  • Chronic Lymphocytic Leukemia Research
  • Cutaneous lymphoproliferative disorders research
  • Amyloidosis: Diagnosis, Treatment, Outcomes
  • Immune Cell Function and Interaction

Lemonnier's recent scientific publications include detailed clinical and molecular studies published in respected journals. Selected works include:

  • "Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial" (2023, Nature Medicine)
  • "Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma" (2021, Blood Advances)
  • "Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome" (2022, Haematologica)
  • "IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment" (2023, Cancer Cell)
  • "Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation" (2021, Leukemia & lymphoma/Leukemia and lymphoma)

Frequent co-authors collaborating with François Lemonnier include:

  • Philippe Gaulard
  • Emmanuel Bachy
  • Laurence de Leval
  • Franck Morschhauser
  • Elsa Poullot

Regular publication venues for Lemonnier span multiple journals, reflecting a consistent contribution to hematology and oncology literature. These venues include:

  • Hematological Oncology
  • Blood
  • HemaSphere
  • European Journal of Cancer
  • Blood Advances

Best Publications

  • Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein

    O Schwartz;V Maréchal;S Le Gall;F Lemonnier

  • Differential Requirements for Survival and Proliferation of CD8 Naïve or Memory T Cells

    Corinne Tanchot;François A. Lemonnier;François A. Lemonnier;Beatrice Pérarnau;Beatrice Pérarnau;Antonio A. Freitas;Antonio A. Freitas

  • Persistence of Memory CD8 T Cells in MHC Class I-Deficient Mice

    Kaja Murali-Krishna;Lisa L. Lau;Suryaprakash Sambhara;Francois Lemonnier

  • HLA-A2.1–restricted Education and Cytolytic Activity of CD8+ T Lymphocytes from β2 Microglobulin (β2m) HLA-A2.1 Monochain Transgenic H-2Db β2m Double Knockout Mice

    Steve Pascolo;Nathalie Bervas;Jan M. Ure;Austin G. Smith

  • An invariant T cell receptor α chain defines a novel TAP-independent major histocompatibility complex class Ib-restricted α/β T cell subpopulation in mammals

    Florence Tilloy;Emmanuel Treiner;Se Ho Park;Corinne Garcia

  • Exosomes as Potent Cell-Free Peptide-Based Vaccine. I. Dendritic Cell-Derived Exosomes Transfer Functional MHC Class I/Peptide Complexes to Dendritic Cells

    Fabrice André;Nathalie Chaput;Nöel E. C. Schartz;Caroline Flament

  • IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.

    Rob A. Cairns;Javeed Iqbal;François Lemonnier;Can Kucuk

  • Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters.

    François Lemonnier;François Lemonnier;Lucile Couronné;Marie Parrens;Jean-Philippe Jaïs

  • Direct Assessment of MHC Class I Binding by Seven Ly49 Inhibitory NK Cell Receptors

    Thomas Hanke;Hisao Takizawa;Christopher W McMahon;Dirk H Busch

  • Exosomes as Potent Cell-Free Peptide-Based Vaccine. II. Exosomes in CpG Adjuvants Efficiently Prime Naive Tc1 Lymphocytes Leading to Tumor Rejection

    Nathalie Chaput;Nöel E. C. Schartz;Fabrice André;Julien Taïeb

  • Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas

    David Vallois;Maria Pamela D. Dobay;Ryan D. Morin;Ryan D. Morin;François Lemonnier

  • Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

    Emmanuel Bachy;John F. Seymour;Pierre Feugier;Fritz Offner

  • Single H2Kb, H2Db and double H2KbDb knockout mice: peripheral CD8+ T cell repertoire and anti-lymphocytic choriomeningitis virus cytolytic responses.

    Béatrice Pérarnau;Marie Françoise Saron;Bernardo Reina San Martin;Nathalie Bervas

  • Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma

    Tayla B. Heavican;Alyssa Bouska;Jiayu Yu;Waseem Lone

  • Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines

    Julien Taieb;Nathalie Chaput;Noël Schartz;Stéphan Roux

  • H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies

    Hüseyin Firat;Francisco Garcia-Pons;Sophie Tourdot;Steve Pascolo

  • Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin.

    Maria Pamela Dobay;Francois Lemonnier;Edoardo Missiaglia;Christian Bastard

  • A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice.

    Anthony Pajot;Marie-Louise Michel;Nicolas Fazilleau;Véronique Pancré

  • A general strategy to enhance immunogenicity of low-affinity HLA-A2.1-associated peptides: implication in the identification of cryptic tumor epitopes

    Sophie Tourdot;Antonio Scardino;Eleanna Saloustrou;David A. Gross

  • Natural killer cell education in mice with single or multiple major histocompatibility complex class I molecules

    Sofia Johansson;Maria Johansson;Eleftheria Rosmaraki;Gustaf Vahlne

  • Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2.

    Satoshi Inoue;Satoshi Inoue;Wanda Y. Li;Wanda Y. Li;Alan Tseng;Alan Tseng;Alan Tseng;Isabel Beerman;Isabel Beerman

  • High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy

    David-Alexandre Gross;Stéphanie Graff-Dubois;Paule Opolon;Sébastien Cornet

  • Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.

    Ingo Drexler;Caroline Staib;Wolfgang Kastenmüller;Stefan Stevanović

  • Major histocompatibility complex (MHC) class I KbDb −/− deficient mice possess functional CD8+ T cells and natural killer cells

    Yulia Vugmeyster;Rickard Glas;Béatrice Pérarnau;François A. Lemonnier

  • Introduction of exogenous antigens into the MHC class I processing and presentation pathway by Drosophila antennapedia homeodomain primes cytotoxic T cells in vivo.

    M P Schutze-Redelmeier;H Gournier;F Garcia-Pons;M Moussa

  • HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy.

    Antonio Scardino;David Alexandre Gross;Pedro Alves;Joachim L. Schultze

  • Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8(+) cytotoxic T-cell epitopes.

    T. Woodberry;J. Gardner;Luis A. Mateo;D. Eisen

  • Cytolytic thymus-derived lymphocytes specific for allogeneic stimulator cells crossreact with chemically modified syngeneic cells.

    Francois Lemonnier;Steven J. Burakoff;Ronald N. Germain;Baruj Benacerraf

  • An HLA-A2 polyepitope vaccine for melanoma immunotherapy.

    Luis Mateo;Joy Gardner;Qiyuan Chen;Christopher Schmidt

  • Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma.

    François Lemonnier;François Lemonnier;Jehan Dupuis;Pierre Sujobert;Olivier Tournillhac

  • ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes.

    Lorena Passoni;Antonio Scardino;Carla Bertazzoli;Barbara Gallo

  • Identification of naturally processed HLA-A2--restricted proinsulin epitopes by reverse immunology.

    Yousra Hassainya;Francisco Garcia-Pons;Roland Kratzer;Vivian Lindo

  • Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant–associated ALCL

    Camille Laurent;Alina Nicolae;Cécile Laurent;Fabien Le Bras

  • Cutting Edge: Expression of Functional CD94/NKG2A Inhibitory Receptors on Fetal NK1.1+Ly-49− Cells: A Possible Mechanism of Tolerance During NK Cell Development

    P. V. Sivakumar;A. Gunturi;M. Salcedo;J. D. Schatzle

  • Quantification by flow cytofluorimetry of HLA class I molecules at the surface of murine cells transformed by cloned HLA genes

    Philippe P. Le Bouteiller;Zohair Mishal;François A. Lemonnier;François M. Kourilsky

Frequent Co-Authors

Philippe Gaulard
Philippe Gaulard Université Paris Cité
Corinne Haioun
Corinne Haioun Paris-Est Créteil University
Salem Chouaib
Salem Chouaib Gulf Medical University
Christian Boitard
Christian Boitard Université Paris Cité
Hervé Tilly
Hervé Tilly University of Rouen
Marie-Louise Michel
Marie-Louise Michel Institut Pasteur
Olivier Danos
Olivier Danos REGENXBIO Inc.
Pierre Ferrier
Pierre Ferrier Aix-Marseille University
Florent Ginhoux
Florent Ginhoux Agency for Science, Technology and Research

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in studying Immunology in the USA, exploring related online degrees can offer diverse career trajectories in healthcare and research. Programs such as nursing often intersect with immunology, providing practical applications in patient care and disease prevention.

If you are considering advancing your nursing career, you might explore the easiest absn programs to get into. These accelerated programs allow individuals with a non-nursing bachelor's degree to earn a Bachelor of Science in Nursing quickly and efficiently, opening doors to clinical immunology roles.

Alternatively, starting with foundational nursing education is crucial, and candidates can find valuable options among the best easiest lpn programs to get into. Licensed Practical Nurses often support immunology research units and hospitals by providing essential patient care.

For advanced practice nurses looking to specialize, knowing what is the easiest np program can help balance education workload with career goals. Nurse practitioners frequently collaborate with immunologists in patient diagnostics and treatment.

Psychiatric roles also intersect with immunological research, especially in neuroimmunology. The best psychiatric mental health nurse practitioner programs online provide robust training with strong clinical placements, supporting mental health care that often integrates immunological perspectives.

Best Scientists Citing François A. Lemonnier

Trending Scientists

Recently Published Articles